Chondromodulating Effect of Diacerein in Osteoarthritis of the Hip
NCT ID: NCT00451360
Last Updated: 2008-07-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
500 participants
INTERVENTIONAL
1993-03-31
1997-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* evaluate the ability of diacerein, an interleukin-1β inhibitor, to slow the progressive decrease in joint space width observed in patients with hip osteoarthritis
* to investigate the potential structure-modifying effect of diacerein in patients with hip osteoarthritis
This study compare also after ten years the percentage of patients in each treatment group who require a hip replacement surgery
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
diacerein
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Lequesne algofunctional index of at list 3 points.
* Radiographic criterion for inclusion: joint space width (JSW) between 1 mm and 3 mm. If the JSW exceeded 3 mm, it had to be at least 0.5 mm thinner than JSW of the contra lateral hip, measured at its narrowest point.
Exclusion Criteria
* Any systemic or intraarticular corticosteroid as well as other potential symptom-modifying drugs for osteoarthritis were not allowed during the study.
50 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Laboratoires NEGMA
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
DOUGADOS Maxime
Role: PRINCIPAL_INVESTIGATOR
Scientific committee
Michel LEQUESNE
Role: PRINCIPAL_INVESTIGATOR
Scientific committee
Bernard MAZIERE
Role: PRINCIPAL_INVESTIGATOR
Scientific committee
Eric VIGNON
Role: PRINCIPAL_INVESTIGATOR
Scientific committee
Laurent BERDAH
Role: PRINCIPAL_INVESTIGATOR
Scientific committee
Minh NGUYEN
Role: PRINCIPAL_INVESTIGATOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hôpital Nord
Amiens, , France
Hôpital Pellegrin
Bordeaux, , France
Hôpital Ambroise Paré
Boulogne, , France
CHU cote de Nacre
Caen, , France
Hôpital Mondor
Créteil, , France
Hôpital Général
Dijon, , France
CHU
Grenoble, , France
Hôpital Roger Salengro
Lille, , France
CHRU Dupuytren
Limoges, , France
Hôpital de la Timone
Marseille, , France
Hôpital Lapeyronie
Montpellier, , France
Hôpital de l'Archet
Nice, , France
Hôpital Cochin, clinique de rhumatologie
Paris, , France
Paris, , France
Hôpital Cochin
Paris, , France
Hôpital Leopold Bellan
Paris, , France
CH Lyon Sud
Pierre-Bénite, , France
CHU Lyon Sud
Pierre-Bénite, , France
Hôpital de la Milétrie
Poitiers, , France
CHR
Rennes, , France
Hôpitam de Bois Guillaume
Rouen, , France
Hôpital de Hautepierre
Strasbourg, , France
CHU de Rangueil
Toulouse, , France
CHU Trousseau
Tours, , France
CHU de Brabois
Vandœuvre-lès-Nancy, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Dougados M, Nguyen M, Berdah L, Mazieres B, Vignon E, Lequesne M; ECHODIAH Investigators Study Group. Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Evaluation of the Chondromodulating Effect of Diacerein in OA of the Hip. Arthritis Rheum. 2001 Nov;44(11):2539-47. doi: 10.1002/1529-0131(200111)44:113.0.co;2-t.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AFSSAPS number: 930289
Identifier Type: -
Identifier Source: secondary_id
CCPPRB number: 469
Identifier Type: -
Identifier Source: secondary_id
HEC / CHO 90040N
Identifier Type: -
Identifier Source: org_study_id